Global Gestational Trophoblastic Disease Market - 2020-2027
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The Global Gestational Trophoblastic Disease Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
A Gestational Trophoblastic Disease (GTD) is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus. These do not develop from the uterus cells like cervical cancer or endometrial (uterine lining) cancer does. Instead, these tumors begin in the cells that would normally develop into the placenta during pregnancy. GTDs begin in the layer of cells called the trophoblast that usually surrounds an embryo. Early in normal development, the cells of the trophoblast form tiny, finger-like projections known as villi. These villi grow into the lining of the uterus, and in time, the trophoblast layer develops into the placenta, the organ that protects and nourishes the growing foetus. Most GTDs are benign (not cancer), and they don't invade deeply into body tissues or spread to other parts of the body. But some are malignant (cancerous). Some signs and symptoms include Vaginal bleeding, Low red blood cell count (anemia), Swelling of the abdomen (belly), Ovarian cysts, Pre-eclampsia (toxic pregnancy). According to the type of gestational trophoblastic disease (GTD) and the stage and prognostic group of the disease, the standard treatment options are surgery, chemotherapy, and radiation therapy.
The global Gestational Trophoblastic Disease market growth is driven by the Uprising in risk factors affecting this spectrum of disease like increase in high maternal age, increase cases for ectopic pregnancies, rise in active smoking habits, growing innovations in the field of oncology and the increase focus towards targeted therapies, along with the favourable government policies are the major factors driving the market.
Uprising in risk factors affecting this spectrum of disease, is expected to drive the growth in the forecast period
Major risk factors affecting GTDs are high maternal age, increased ectopic pregnancies and active smoking habits. GTD occurs in women of childbearing age. The risk of complete molar pregnancy is highest in women over age 35 and younger than 20. As per the American Lung Association, cigarette smoking kills an expected 201,770 women annually in the U.S because the risk of ectopic pregnancy is 4 to 20 times higher in women who smoke. These factors are driving the growth of the market in the forecast period.
High treatment costs are likely to hinder the market growth.
According to the National Library of Medicine, First-line chemotherapy for low-risk gestational trophoblastic neoplasia is $9,089 average cost per cure and for high-risk it costs even high. These are one of the major factors restricting the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually
Based on the Type, the global Gestational Trophoblastic Disease market is segmented into Hydatidiform mole (complete or partial, Invasive mole), Choriocarcinoma, Placental-site trophoblastic tumor, Epithelioid trophoblastic tumor.
Gestational trophoblastic disease (GTD) is a rare form of tumor occurs in about 1 pregnancy out of 1,000 in the United States. Most of these are hydatidiform moles. Choriocarcinoma, a malignant form of gestational trophoblastic disease (GTD), is even less common, affecting around 2 to 7 of every 100,000 pregnancies.
Hydatidiform mole segment, is expected to hold the largest in the market.
The most common form of the gestational trophoblastic disease (GTD) is a hydatidiform mole, and it is also known as a molar pregnancy. It is made up of villi that have become swollen with fluid. The swollen villi grow in clusters that look like bunches of grapes. It is called a molar pregnancy, but a normal baby can't form. Still, in rare cases (less than 1 in 100), a normal foetus can develop alongside the molar pregnancy. Hydatidiform moles are not cancerous, but they can develop into cancerous GTDs. For instance, Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles by Baylor College of Medicine is expected to complete by 2025 which will increase the demand for this segment.
Based on the Treatment Type, the global Gestational Trophoblastic Disease market is segmented into Chemotherapy, Surgery, Radiation therapy and Others.
Chemotherapy segment, is expected to hold the largest in the market.
Chemotherapy treatment uses anti-cancer drugs that are injected into a vein or given by mouth. These drugs enter the bloodstream and reach all areas of the body, making this treatment useful for cancers that have spread to distant organs (metastasized). Gestational trophoblastic disease (GTD) is one of the few cancers that can almost always be cured by chemo, no matter how advanced it is. The drugs that can be used to treat GTD include Methotrexate (with or without leucovorin), Actinomycin-D (dactinomycin), Cyclophosphamide (Cytoxan®), Chlorambucil, Vincristine (Oncovin®), Etoposide (VP-16), Cisplatin, Ifosfamide (Ifex®), Bleomycin, Fluorouracil (5-FU), Paclitaxel (Taxol®).
Based on End-User, the global Gestational Trophoblastic Disease market is segmented into Hospitals, Diagnostic Centers, Clinics, others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.
North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, in 2018, Novartis AG Company entered into a license and collaboration agreement with Cellular Biomedicine Group, a clinical stage biopharmaceutical company which improves therapies for cancer and degenerative diseases in China.
The Global Gestational Trophoblastic Disease Market is quite competitive with some key competitors like Bristol-Myers Squibb Company, Antares Pharma, Novartis AG, Teva Pharmaceutical Industries Ltd, BP Pharmaceuticals Laboratories Company, Accord Healthcare, Inc, Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc, Merck Healthcare KGaA. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, Eli Lilly and Company - A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor.
Merck Healthcare KGaA
Company Overview: Merck KGaA, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. They are headquartered in Darmstadt, with about 58,000 employees and present in 141 countries. The group includes around 250 companies; the leading company is Merck KGaA in Germany. They drive innovation and back entrepreneurs through equity investments and hands-on support in fields that could impact our current and future business. Between our Amsterdam headquarters and American and Israeli offices, our M Ventures team has €300 million under management across four fields: Healthcare, Life Science, Electronics and New Businesses.
Product Portfolio: The Company's portfolio comprised of include Endocrinology, Neurodegenerative diseases, Oncology, Fertility, General medicine and others.
TROPHAMET, a Phase I/II Trial of Avelumab and Methotrexate in Low-risk Gestational Trophoblastic Disease as First Line Treatment.
The global Gestational Trophoblastic Disease Market report would provide an access to an approx. 61 market data table, 58 figures and 240 pages.
LIST NOT EXHAUSTIVE